Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Working Capital Changes (2019 - 2025)

Historic Other Working Capital Changes for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to -$192000.0.

  • IDEAYA Biosciences' Other Working Capital Changes fell 12014.69% to -$192000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 3368.88%. This contributed to the annual value of $6.2 million for FY2024, which is 14489.2% up from last year.
  • IDEAYA Biosciences' Other Working Capital Changes amounted to -$192000.0 in Q3 2025, which was down 12014.69% from $500000.0 recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Other Working Capital Changes registered a high of $3.1 million during Q1 2024, and its lowest value of -$26.3 million during Q3 2022.
  • For the 5-year period, IDEAYA Biosciences' Other Working Capital Changes averaged around -$4.0 million, with its median value being -$2.0 million (2021).
  • Per our database at Business Quant, IDEAYA Biosciences' Other Working Capital Changes plummeted by 48205.66% in 2021 and then soared by 22050.03% in 2024.
  • Over the past 5 years, IDEAYA Biosciences' Other Working Capital Changes (Quarter) stood at -$2.0 million in 2021, then tumbled by 96.21% to -$3.8 million in 2022, then soared by 62.41% to -$1.4 million in 2023, then surged by 220.5% to $1.7 million in 2024, then tumbled by 111.07% to -$192000.0 in 2025.
  • Its last three reported values are -$192000.0 in Q3 2025, $500000.0 for Q2 2025, and $2.0 million during Q1 2025.